Blue Owl Capital

“Latigo Biotherapeutics 'Raised $345.6 million in its IPO'”

“Blue Owl Capital-backed biotech company Latigo Biotherapeutics, which develops pain medicines, is seeking to raise up to $288 million in its IPO.”

“Has secured $10.6b for its sixth GP stakes fund, which is targeting a total of $13b.”